XSES
8K7
Market cap36mUSD
Nov 02, Last price
0.07SGD
1D
-2.67%
1Q
-5.19%
Jan 2017
-23.16%
IPO
-0.45%
Name
UG Healthcare Corporation Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
UG Healthcare Corporation Limited, an investment holding company established in Singapore in 1989, primarily engages in the manufacturing and worldwide distribution of disposable gloves. Its business is structured across three main segments: Latex Examination Gloves, Nitrile Examination Gloves, and a category for Other Ancillary Products. The company's offerings include both latex examination gloves, available in single and double chlorinated polymer-coated varieties, as well as nitrile examination gloves. Additionally, it supplies a range of supplementary items like surgical gloves, vinyl and cleanroom disposable gloves, face masks, various other medical disposables, and protective shoe covers. The firm also extends its expertise through business and management consultancy services. Its products serve diverse sectors such as healthcare, food and beverage, industrial and high-technology manufacturing, automotive, research and development, and the beauty industry. Operating under its "Unigloves" brand name, the corporation reaches customers across Malaysia, Europe, North America, South America, Africa, and the broader Asian market.
Key people
Jun Yih Lee
Joint-Chief Executive Officer, Finance Director, Executive Director · since 2025
Keck Keong Lee
Executive Director · since 2025
Jun Linn Lee
Joint-Chief Executive Officer, Chief Operating Officer, Executive Director · since 2025
See Keong Wong
Executive Director · since 2014
Pek Wee Wong
Head of Manufacturing
Mei Mei Low
Company Secretary · since 2021
Non-Executive Independent Chairman of the Board · since 2024
Non-Executive Independent Director · since 2024
Lee Eng Ng
Non-Executive Independent Director · since 2023
IPO date
Dec 08, 2014
Employees
1,076
Domiciled in
MY
Incorporated in
SG
Valuation
Title SGD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||